Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)
摘要:
Following our discovery of human dihydroorotate dehydrogenase (DHODH) inhibition by 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as well as 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-methylpyridine, we describe here the syntheses and evaluation of an array of azine-bearing analogues. As in out previous report, the structure activity study of this series of human DHODH inhibitors was based on a phenotypic assay measuring measles virus replication. Among other inhibitors, this round of syntheses and biological evaluation iteration led to the highly active 5-cyclopropyl-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-3-fluoropyridine. Inhibition of DHODH by this compound was confirmed in an array of in vitro assays, including enzymatic tests and cell-based assays for viral replication and cellular growth. This molecule was found to be more active than the known inhibitors of DHODH, brequinar and teriflunomide, thus opening perspectives for its Use as a tool or for the design of an original series of immunosuppressive agent. Moreover, because other Series of inhibitors of human DHODH have been found to also affect Plasmodium falciparum DHODH, all the compounds were assayed for their effect on P. falciparum growth. However, the modest in vitro inhibition solely observed for two compounds did not correlate with their inhibition of P. falciparum DHODH.
Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)
摘要:
Following our discovery of human dihydroorotate dehydrogenase (DHODH) inhibition by 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as well as 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-methylpyridine, we describe here the syntheses and evaluation of an array of azine-bearing analogues. As in out previous report, the structure activity study of this series of human DHODH inhibitors was based on a phenotypic assay measuring measles virus replication. Among other inhibitors, this round of syntheses and biological evaluation iteration led to the highly active 5-cyclopropyl-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-3-fluoropyridine. Inhibition of DHODH by this compound was confirmed in an array of in vitro assays, including enzymatic tests and cell-based assays for viral replication and cellular growth. This molecule was found to be more active than the known inhibitors of DHODH, brequinar and teriflunomide, thus opening perspectives for its Use as a tool or for the design of an original series of immunosuppressive agent. Moreover, because other Series of inhibitors of human DHODH have been found to also affect Plasmodium falciparum DHODH, all the compounds were assayed for their effect on P. falciparum growth. However, the modest in vitro inhibition solely observed for two compounds did not correlate with their inhibition of P. falciparum DHODH.
[DE] AMID-SUBSTITUIERTE 1,2,4-TRIAZIN-5 (2H)-ONE ZUR BEHANDLUNG VON CHRONISCH INFLAMMATORISCHEN KRANKHEITEN<br/>[EN] AMIDE-SUBSTITUTED 1,2,4-TRIAZIN-5(2H)-ONES FOR THE TREATMENT OF CHRONICALLY INFLAMMATORY DISEASES<br/>[FR] 1,2,4-TRIAZINO-5(2H)-ONES A SUBSTITUTION AMIDE DESTINEES AU TRAITEMENT DE MALADIES INFLAMMATOIRES CHRONIQUES
申请人:BAYER HEALTHCARE AG
公开号:WO2005003118A1
公开(公告)日:2005-01-13
Die Erfindung betrifft Amid-substituierte 1,2,4-Triazin-5(2H)-one und Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere von chronisch inflammatorischen Erkrankungen, wie z.B. Erkrankungen des rheumatoiden Formenkreises, und Herz-Kreislauf-Erkrankungen, wie z.B. Dyslipidämien, Arteriosklerose und koronare Herzerkrankungen Formel (I).
Transformation of a Cu
<sup>II</sup>
Thiazolo‐1,2,4‐triazine Derivative from a Metastable Coordination Network to a Monomer in Solution and Vapor Conditions
through bis(μ-chloro) linkages in a 2-propanol solution. The crystals show dynamic and irreversible structural transformation into blue crystals of [CuCl2(3a)2] (6a; Cu/3a = 1:2) not only in solution but also in vapor conditions. As 5a and 6a are ferromagnetic and paramagnetic, respectively, the transformation of 5a was monitored by magnetic susceptibility measurements in the solidstate, and χT of 5a decreased